Theriva Biologics, Inc. (TOVX)

Import this data to Google Sheets with:

=jivedata("TOVX","financials")

Full statements spill as a table. For one cell: =jivedata("TOVX","Revenue") or =jivedata("TOVX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Theriva Biologics, Inc.

TOVX • CIK 0000894158

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
General and Administrative Expense	$7,120	$7,396	$15,447	$6,918
Research and Development Expense	$14,311	$12,031	$8,604	$5,306
Operating Income (Loss)	$-21,431	$-26,346	$-24,051	$-11,924
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	—	$1,325	$0	$0
Goodwill, Impairment Loss	—	$5,594	$5,594	$5,594
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-19,989	$-25,653	$-23,739	$-11,618
Operating Expenses	$21,431	$26,346	$24,051	$12,224
Income Tax Expense (Benefit)	$-1,640	$0	—	$0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-18,349	$-25,653	$-23,739	$-11,618
Net Income (Loss) Available to Common Stockholders, Basic	$-18,349	$-25,653	$-25,249	$-13,128
Weighted Average Number of Shares Outstanding, Basic	16,107,014	1,348,126	12,140,697	50,858,040
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$711	$-1,210	$1,933	$-546
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$-17,638	$-26,863	$-21,806	$-12,164
Foreign Currency Transaction Gain (Loss), before Tax	$3	$-4	$25	$29
Investment Income, Interest	$1,439	$697	$287	$298
Nonoperating Income (Expense)	$1,442	$693	$312	$306

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$23,177	$11,609	$13,056	$11,337
Grants Receivable, Current	$1,812	$3,228	$3,351	$1,681
Prepaid Expense and Other Assets, Current	$2,414	$1,444	$1,060	$653
Assets	$55,219	$35,352	$38,239	$34,857
Assets, Current	$27,403	$16,281	$17,467	$13,671
Property, Plant and Equipment, Net	$422	$270	$222	$173
Restricted Cash, Noncurrent	$102	$96	$46	$44
Operating Lease, Right-of-Use Asset	$1,759	$1,272	$803	$1,825
Liabilities	$15,522	$16,285	$22,856	$22,670
Intangible Assets, Net (Excluding Goodwill)	$19,755	$17,358	$19,619	$19,064
Accounts Payable, Current	$770	$859	$1,014	$984
Accrued Liabilities, Current	$2,995	$3,368	$6,276	$6,418
Employee-related Liabilities, Current	$1,517	$1,144	$443	$290
Loans Payable, Current	$63	$61	$57	$34
Operating Lease, Liability, Current	$487	$539	$549	$525
Liabilities, Current	$6,738	$7,585	$10,014	$12,111
Business Combination, Contingent Consideration, Liability, Noncurrent	$6,274	$6,973	$10,004	$7,169
Loans Payable, Noncurrent	$162	$92	$1,671	$1,620
Operating Lease, Liability, Noncurrent	$1,442	$873	$352	$1,374
Common Stock, Value, Issued	$18	$3	$34	$45
Additional Paid in Capital, Common Stock	$346,519	$355,501	$373,592	$376,154
Treasury Stock, Value	$288	$288	$288	$288
Accumulated Other Comprehensive Income (Loss), Net of Tax	$32	$-1,178	$755	$247
Retained Earnings (Accumulated Deficit)	$-309,318	$-334,971	$-358,710	$-363,971
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$36,963	$19,067	$15,383	$12,187
Common Stock, Shares Authorized	350,000,000	350,000,000	350,000,000	350,000,000
Common Stock, Shares, Issued	17,868,282	2,811,258	35,717,159	45,921,478
Common Stock, Shares, Outstanding	17,148,049	2,782,449	35,688,350	45,892,668
Treasury Stock, Common, Shares	720,233	28,809	28,809	28,810

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-18,349	$-25,653	$-23,739	$-11,618
Net Cash Provided by (Used in) Operating Activities	$-18,996	$-16,937	$-16,669	$-12,742
Net Cash Provided by (Used in) Investing Activities	$-202	$-1	$-35	$-22
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$-33	$-132	$-92	$-183
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-18,606	$-11,574	$1,397	$-785
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$23,279	$11,705	$13,102	$17,464
Share-based Payment Arrangement, Noncash Expense	$552	$671	$654	$651
Payments to Acquire Property, Plant, and Equipment	$202	$1	$35	$22
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	—	$1,325	$0	$0
Goodwill, Impairment Loss	—	$5,594	$5,594	$5,594
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$-660	$699	$9,031	$-327
Gain (Loss) on Disposition of Assets	—	—	$1	$1
Depreciation, Depletion and Amortization	$135	$137	$108	$103
Proceeds from (Repayments of) Notes Payable	—	—	$-70	$-63
Proceeds from Issuance of Long-term Debt	—	—	$1,507	$1,507
Proceeds from Warrant Exercises	$8,000	—	$4	$4
Net Cash Provided by (Used in) Financing Activities	$625	$5,496	$18,193	$12,162
Cash and Cash Equivalents, at Carrying Value	$23,177	$11,609	$13,056	$17,473
Restricted Cash and Cash Equivalents	$102	$96	$46	$-9
Increase (Decrease) in Prepaid Expense and Other Assets	$-1,368	$-912	$-456	$-243
Increase (Decrease) in Deposit Assets	$54	$-1	$1	$1
Increase (Decrease) in Accounts Payable	$-157	$123	$69	$362
Increase (Decrease) in Accrued Liabilities	$1,470	$522	$-2,277	$-1,479
Increase (Decrease) in Employee Related Liabilities	$104	$-350	$-744	$-464
IncreaseDecreaseInOperatingLeaseLiability	$-422	$-482	$-562	$-572

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("TOVX","financials")

Full statements spill as a table. For one cell: =jivedata("TOVX","Revenue") or =jivedata("TOVX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.